ホーム » カタログRNA＆LNP製品 » PEmax mRNA (Cap1, m1Ψ)

PEmax mRNA (Cap1, m1Ψ)

*This product is under development*
The PEmax mRNA expresses an optimized prime editor enzymatic protein, which further increased editing efficiency in synergy with PE4, PE5 and engineered pegRNAs (Chen P, et al. 2021, Cell 184, 5635-5652). This mRNA is capped with Cap1-AG structure with high capping efficiency. It has 100% substituted with N1-methylpseudouridine for enhanced expression and reduced immunogenicity. The mRNA has a 100A tail in its sequence. After efficient delivery, PEmax mRNA can translate into protein including a nickase and reverse transcriptase function for gene editing in cells.
RP-A00045
Ask us a question
Description

The PEmax mRNA expresses an optimized prime editor enzymatic protein, which further increased editing efficiency in synergy with PE4, PE5 and engineered pegRNAs (Chen P, et al. 2021, Cell 184, 5635-5652). After efficient delivery into cells or animals, PEmax mRNA can translate into protein including a nickase and reverse transcriptase function for gene editing in cells.  
 
This mRNA features: 
- A Cap 1 structure with high capping efficiency 
- 100% substitution with N1-methyl-pseudouridine (m1Ψ) for improved protein expression and reduced innate immune response 
- GenScript’s patented UTR to enhance translation 
- A 100A poly(A) tail to mimic natural mature mRNA
Properties
Form Liquid
Concentration 1mg/mL
Full mRNA length 6660nt
Full mRNA Molecular Weight 2.15 X 10^6 Da
Storage buffer 1mM Sodium citrate, pH6.5
Storage condition Store at -20°C for short term (<3 months), store at -80°C for long term.

Quality Control Specifications
Appearance Clear and free of foreign particles
RNA Length Expected size band detected
RNA Content Target ± 5%
Integrity ≥ 75%
OD260/OD280 1.70 ~ 2.30
Capping Efficiency ≥ 90%
Endotoxin < 10 EU/mg
pH Target ± 0.5

Applications
Transfect a total of 2 µg of PEmax mRNA and pegRNA per well, using a transfection reagent, electroporation, or LNP encapsulation in a 24-well plate (~2 × 10⁵ cells/well). Assess genome editing efficiency 48-72 hours post-transfection via sequencing.

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.